Patient with very high cardiovascular risk and long-standing T2DM: a case report

Czech version

Authors: Olga Bobelová
Authors‘ workplace: DIOLI s. r. o., Košice
Published in: Diab Obez 2024; 24(48): 137-140
Category: Case studies

Sources

Lacka J, Martinka E, Uličiansky V et al [Slovenská diabetologická spoločnosť, Ministerstvo zdravotníctva SR]. Komplexný manažment diabetikov 2. typu. 1. revízia. Štandardné postupy, Ministerstvo zdravotníctva Slovenskej republiky: Bratislava 2024. Dostupné online z WWW: <https://www.standardnepostupy.sk/standardy-diabetologia/> a tlačou v Diab Obez 2024; 24(Suppl).

McDonagh TA , Metra M, Adamo M et al. [ESC Scientific Document Group]. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023; 44(37): 3627–3639. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehad195>. Erratum in Eur Heart J 2024; 45(1): 53. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehad613>.

Standards of Care in Diabetes – 2023. American Diabetes Association. Diabetes Care 2023; 46(suppl 1): S1-S298. Dostupné z WWW: <https://diabetesjournals.org/care/issue/46/Supplement_1>.

Buse JB, Wexler DJ, Tsapas A et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020; 43(2): 487–493. Dostupné z DOI: <http://dx.doi.org/10.2337/dci19–0066>. Erratum in: Diabetes Care 2020; 43(7): 1670. Dostupné z DOI: <http://dx.doi.org/10.2337/dc20-er07>.

Rossing P, Caramori ML, Chan JC et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int 2022; 102(5): 990–999. Dostupné z DOI: <http://dx.doi.org/10.1016/j.kint.2022.06.013>.

Martinka E, Tkáč I, Mokáň M (eds) et al. Odporúčané postupy pre liečbu diabetes mellitus 2. typu – 2023. Forum Diab 2023; 12(2): 91–133.

Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380(4): 347–357. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1812389>.

Heerspink HJ, Stefánsson BV, Correa-Rotter R et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383(15): 1436–1446. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2024816>.

Zoznam kategorizovaných liekov 1. 11. 2024 – 31. 11. 2024. Dostupné z WWW: <https://www.health.gov.sk/?zoznam-kategorizovanych-liekov>.